icp-723
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 27, 2020 (NCT04685226)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
NTRK2 inhibitor
NTRK3 inhibitor
- Nerve growth factor receptor Trk-AINHIBITOR
NTRK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05745623 | Phase 1/Phase 2 (Phase 2) | Dec 27, 2022 | Beijing InnoCare Pharma Tech Co., Ltd., Sun Yat-Sen University |
| NCT05537987 | Phase 1 | Jul 30, 2021 | Beijing InnoCare Pharma Tech Co., Ltd., University of Kansas |
| NCT04685226 | Phase 1/Phase 2 (Phase 2) | Sep 27, 2020 | Beijing InnoCare Pharma Tech Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing InnoCare Pharma Tech Co., Ltd. | For profit | 3 | 3 | 2 | 2020 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Kansas | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1